VS411, ViroStatics' clinical Proof of Concept product for the use of AV-HALTs in the treatment of HIV/AIDS, combines the antiviral activity of low-dose, slow-release dideoxyinosine with the antiproliferative properties of low-dose hydroxycarbamide. The two agents, each of which have been employed in the clinical setting for many years, have been formulated together in a fixed dose combination product known as VS411.

Beneficial synergies between the drugs' mechanisms of action, combined with hydroxycarbamide’s immunomodulating properties and the combination’s favorable resistance profile against dideoxyinosine-resistant HIV, allowed for the investigation of lower doses of each drug than are currently prescribed.

If you would like additional information about any of the studies listed below, please contact:

Michael Stevens, PharmD
Chief Strategy Officer
116 Village Boulevard Suite 200 - Princeton, NJ 08540
Phone: +1 609 951-2206 - Mobile: +1 609 213-5287
M.Stevens@virostatics.com